0.1 μm and less than or equal to 10 μm~~, and the average size particle of the pulverized carrier is in a range of 30 to 120 μm~~.

What is claimed is:

1. A dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate, tiotropium bromide, and a carrier,

wherein the dry powder has an average particle size in a range of 55 to 65 μm, and

the amount of the carrier employed is in the range of 15 mg to 25 mg per unit dose of the formulation.

2. The dry powder for inhalation formulation of claim 1, wherein the carrier is selected from the group consisting of monosaccharides, disaccharides, polysaccharides, polyalcohols and hydrates thereof.

3. The dry powder for inhalation formulation of claim 2, wherein the carrier is lactose monohydrate.

4. An inhalation formulation comprising the dry powder of claim 1.

5. The inhalation formulation of claim 4, wherein salmeterol xinafoate, fluticasone propionate and tiotropium bromide are employed in amounts of 25 to 100 μg, 25 to 500 μg, and 5 to 50 μg, per unit dose of the formulation, respectively.

6. A method for preparing the dry powder for inhalation formulation of claim 1, which comprises the steps of:

(1) applying 5 to 20 wt% of the carrier, based on the total amount of the carrier, onto inner wall of a mixer;

(2) triturating salmeterol xinafoate, fluticasone propionate and tiotropium bromide with 5 to 20 wt% of the carrier, based on the total amount of the carrier; and

(3) mixing and pulverizing the triturated ingredients and the remaining carrier in the mixer prepared in Step (1).

7. The method for preparing the dry powder for inhalation formulation of claim 6, wherein the average size particle of said pulverized ingredients is greater than

0.1 μm and less than or equal to 10 μm.